Jan M. Troup, Ph.D
President, CEO and Inventor
LipidRisk LLC, HDL3-P Activation, Consulting
Dr. Troup has over 45 years’ experience in the development of new analytical technology and addressing a need, with an innovative approach, to provide technology to the public market. He earned a Ph.D. in Chemistry from Texas A&M University in 1974, and is the author of 50 scientific publications mainly in synthetic inorganic chemistry and single crystal x-ray crystallography and x-ray structure determination. He was awarded the Distinguished Graduate Student Award from Texas A&M University in 1973. While a graduate student he founded Molecular Structure Corporation (MSC), the world’s first single crystal x-ray crystallographic service company. Single crystal x-ray diffraction is the most powerful laboratory tool available to view new molecules at the atomic level, especially in the biotechnology research arena. MSC’s products were used for the technique known as structure-based drug design and are partly responsible for the discovery of many new drugs on the market today. MSC’s success lead to the formation of service crystallography departments in Universities and companies worldwide.
Developing the company in the scientific markets, Dr. Troup negotiated and exclusive agreement in 1984 with Rigaku Corporation, a Japanese company, to sell and develop instruments for single crystal x-ray diffraction in North America. By 1988 MSC had extended its territory to most of the global and scientific market, establishing an office in Germany. Under Dr. Troup’s guidance, MSC imported, marketed, sold, installed and serviced Rigaku x-ray instruments worldwide. The product included instrumentation from Rigaku, MSC’s computers, software, cryogenic devices, positioning tables, x-ray optics, enclosures and other accessories. By 1996 MSC had 50 employees in The Woodlands, Texas, and two offices in Europe with seven employees. The company had research and development, sales and marketing, financial, import and export, and field service departments as well as a design and manufacturing facility with CNC equipment. MSC maintained a 60% global market share and a 20% annual growth rate from 1985 to 1996 with sales reaching $15 million.
Dr. Troup served as President and CEO of MSC for 23 years until he sold the company in 1996 to Rigaku Corporation. In 1997 Dr. Troup formed the company Aquavit, Inc., a manufacture of scuba diving products. The company is the result of a 20 year hobby in scuba diving and an interest to improve the safety of diving. Aquavit, Inc. manufactures the X-tra System, a self rescue system for divers and other diving products. In 2000 Dr. Troup was issued a U.S. patent on the novel X-tra System. In 2000 Dr. Troup was appointed as a member of the Texas A&M University, College of Science, External Advisory and Development Council and in 2002 received the Distinguished Graduate Award from the College of Science of Texas A&M University.
In 2001 Dr. Troup started LipidLabs, Inc., a CLIA certified laboratory in the area of lipoprotein analysis from research initiated at Texas A&M University. Over a four year period Dr. Troup continued the development of the technology into a commercial product that was introduced to physicians in 2002 to better diagnosis and treat patients for cardiovascular disease. In 2003 Dr. Troup filed a patent on the innovations resulting from the LipidLabs research and development. The US Patent 7856323 was issued after revision in 2011. LipidLabs, Inc. became publicly traded in 2004 and formed a subsidiary named LPLB Investments. LPLB Investments underwent two reverse mergers and currently exist as Texas Developing Technologies, Inc. with Dr. Troup serving as President and CEO until 2014.
LipidLabs, Inc. sold the assets for the advanced lipoprotein subgroup analysis to SpectraCell Laboratories in January of 2006 and Dr. Troup joined SpectraCell as Director of Lipid Science. The advanced lipoprotein test is marketed and sold nationally to physicians as the Lipoprotein Particle Profile or LPP with approximately 30,000 tests performed annually. In 2018 Dr. Troup left SpectraCell Laboratories and formed LipidRisk, LLC to explore methods in lipoprotein testing for the identification of new lipoprotein risk factors.
Other areas of interest include research on a the "Time of Injury" treatment for concussion and TBI using gallium compounds described in the utility patent by Jan M. Troup issued on 12-8-2015 and a treatment for cardiovascular disease using gallium compounds described in the utility patent by Jan M. Troup issued on 12-17-19.